Expert Opinion on Biological Therapy

Article	Citations
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm cli	76
Biosimilars and access to biologic therapy in immune-mediated diseases	59
Management of chronic recurrent multifocal osteomyelitis: review and update on the treatment protocol	58
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males	54
The endosomal-lysosomal system in ADC design and cancer therapy	53
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases	43
Combining VEGF and PD-1/PD-L1 inhibition in advanced hepatocellular carcinoma: clinical trials, real-world evidence, and future directions	41
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?	32
Aflibercept biosimilars – so near, yet so far	32
Antibody drug conjugates for glioblastoma: current progress towards clinical use	31
IL-4/IL-13 targeted biologics in atopic dermatitis: is their use safe in oncologic patients?	31
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences	28
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era	28
Bispecific antibody combination regimens for B-cell non-Hodgkin’s lymphomas	28
Signaling new therapeutic opportunities: cytokines in prostate cancer	27
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)	26
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway	26
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden	26
Correction	25
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma	25
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?	24
Long-acting delivery and therapies for neovascular age-related macular degeneration	23
Targeting the neuroimmune axis in prurigo nodularis: a critical appraisal of the nemolizumab trials	23
Dual clinical remission in severe asthma and chronic rhinosinusitis with nasal polyps: a comparative review of biologic therapies	22
Development and Clinical Translation Considerations for the Next Wave of Gene Modified Hematopoietic Stem and Progenitor Cells Therapies	22

What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?	21
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study	21
Unmet needs in cervical cancer – can biological therapies plug the gap?	21
Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)	21
An evaluation of guselkumab for the treatment of ulcerative colitis	21
Correction	20
Predicting and overcoming poor patient responses to sublingual immunotherapy for allergic diseases	20
Non-canonical function of erythropoietin and downstream effects of erythropoietin-mediated signaling beyond its role in erythropoiesis	20
Cell population data as predictive biomarkers for biologic therapy response in psoriasis	20
Correction	20
Challenges and considerations in developing trispecific CAR-Ts for B-cell malignancies	20
Reduced doses of biological therapies in psoriasis: a new potentially “sustainable” frontier of psoriasis treatment	19
New biological agents in systemic lupus erythematosus	19
Strategies for extending the half-life of biotherapeutics: successes and complications	19
Dynamics of biological markets with multiple biosimilar competitors in the United States	18
Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses	18
Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective	18
Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biology	18
Biologic therapy for chronic spontaneous urticaria in pediatrics and adolescents: current landscape, challenges, and future perspectives	17
Management of proctitis in ulcerative colitis and the place of biological therapies	16
Progress towards the clinical use of antimicrobial peptides: challenges and opportunities	16
With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?	16
Review of emerging biological therapies for recurrent and advanced metastatic cervical cancer	16
Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors	16
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies	16
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer’s disease	16
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma	16
The nail in psoriatic arthritis: new insights into prognosis and treatment	16
Sibeprenlimab, which neutralizes A PRoliferation Inducing Ligand (APRIL), as a new approach to treating IgA nephropathy	16
Emerging strategies for the prevention and management of chronic graft-versus-host disease	15
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward	15
Recent advances in delivering RNA-based therapeutics to mitochondria	14
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19	14
Comparative efficacy, safety and immunogenicity of biosimilars and their reference biologic drugs in ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials	14
The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region	14
Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis	14
Personalizing immunotherapy for renal cell carcinoma: how far have we come?	13
Psoriatic arthritis improved on risankizumab: does the presence of psoriatic arthritis mean a drug approved for psoriatic arthritis has to be prescribed?	13
Microbiome therapeutics for the treatment of recurrent Clostridioides difficile infection	13
Emerging peptide-based technology for biofilm control	13
Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children	13
The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations	13
State of the art of the molecular hyperselection to guide treatment with anti-EGFR antibodies in RAS WT mCRC: implications for clinical practice and future perspectives	12
Trajectories of biologic drug use before, during and after pregnancy: an Italian cohort study from the VALORE project	12
Belimumab patient profile in Spain: evolution during the last decade and future directions	12
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma	12
An evaluation of pozelimab for the treatment of CHAPLE disease	12
Evaluation of biological treatment in pediatric patients with familial Mediterranean fever: a retrospective study of 832 patients	12
Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan	12
Treating psoriasis in the elderly: biologics and small molecules	12

Talquetamab for the treatment of relapsed/refractory multiple myeloma: a review of efficacy, safety, and real-world evidence	12
Tarlatamab for small-cell lung cancer	12
Assessment of cell-binding capacity of shed rAAV particles after gene therapy vector administration: implications for environmental risk and hygiene recommendations	12
Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)	12
Recent developments and future clinical prospects of polyclonal antibody therapies	11
Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents	11
Correction	11
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective	11
Fecal microbiota transplantation: a review on current formulations inClostridioides difficileinfection and future outlooks	11
A randomized, double-blind, single-dose, parallel two-group study comparing the pharmacokinetics, safety, and immunogenicity of BAT1806 SC with tocilizumab in healthy Chinese male subjects	11
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era	11
Biosimilars in osteoporosis treatment: focus on denosumab	11
Long-term effectiveness and safety of ustekinumab in patients with Crohn’s disease: real-world evidence	11
An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis	11
Efficacy, safety, and ARIA risk of anti–β-amyloid antibodies in early Alzheimer’s disease: a systematic review, meta-analysis, and meta-regression	11
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study	11
Tremelimumab for the treatment of hepatocellular carcinoma	11
The role of monoclonal antibodies in the treatment of lupus nephritis	10
Prospects of cell chemotactic factors in bone and cartilage tissue engineering	10
An evaluation of mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma	10
Clinical management and innovation in fracture non-union	10
Pooled safety analysis from the VOLTAIRE clinical trials of adalimumab-adbm and adalimumab reference product in patients with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis	10
Epcoritamab in B-cell malignancies: current status and prospects	10
Targeting virus-specific CD8+ T cells for treatment of chronic viral hepatitis: from bench to bedside	10
Non-traditional approaches for control of antibiotic resistance	10
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study	10
Personalized therapy in metastatic colorectal cancer: biomarker-driven use of biologics	10
Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms	9
Antibody therapeutics for epithelial ovarian cancer	9
X-linked myotubular myopathy: an untreated treatable disease	9
Biologics in rectal cancer	9
Sargramostim in acute radiation syndrome	9
Current status and future potential of CD123-based targeted therapies for acute leukemia	9
The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target	9
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer	9
Correction	9
Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials	9
An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio	9
Perspectives on the use of biological therapies for the treatment of asthma in low-middle income countries	9
“Full-naïve” patients: the impact of previous methotrexate, cyclosporine, and acitretin on first-line biologics response in the treatment of moderate-to-severe psoriasis – a monocentric retrospective	8
An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa	8
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?	8
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups	8
Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells	8
Perceptions of patients with inflammatory bowel diseases on switching from reference product adalimumab to biosimilar adalimumab-atto	8
Ex vivo gene therapy for lysosomal storage disorders: future perspectives	8
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis	8
Ravulizumab for the treatment of myasthenia gravis	8
Biologic therapy through caregivers’ eyes: insights from a multicenter pediatric rheumatology survey	8
The future of interleukin gene therapy in head and neck cancers	8
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study	8
Expression of Concern:	8
Advances in the management of giant cell arteritis–aortitis: biologic therapies and beyond - a narrative review	7
Effectiveness of biological therapy in reducing psoriasis-related cardiovascular risk	7
Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting	7
Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease	7
Treatment options for advanced hepatocellular carcinoma: the potential of biologics	7
The role of targeted therapies in blastic plasmacytoid dendritic cell neoplasm	7
Long-term progression-free survival in non-small cell lung cancer patients: a spotlight on bevacizumab and its biosimilars	7
Monoclonal antibodies against pediatric ulcerative colitis: a review of clinical progress	7
The future of cellular therapy for the treatment of renal cell carcinoma	7
Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomiz	7
Belantamab mafodotin in multiple myeloma	7
Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations	7
The future of aptamers in cancer diagnosis, prognosis and treatment	7
Improving health literacy and patient-directed knowledge of fecal microbiota transplantation (FMT) through analysis of readability: a cross-sectional infodemiology study	7
Non-TNF biologics and their biosimilars in rheumatoid arthritis	7
Monoclonal antibodies in the management of hereditary angioedema	7
CAR T cells for solid tumors – developments to watch in 2023	7
Second-line strategies after anti-TNF failure in chronically active, moderate-to-severe ulcerative colitis: a retrospective, multicentre cohort study	7
Perspectives on the de-escalation of anti-CD20 monoclonal antibodies in patients with multiple sclerosis	7
Will zilebesiran, an RNA interference therapy, be effective, safe, and improve the treatment of hypertension?	7
An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis	7
Monoclonal antibodies for the management of central nervous system diseases: clinical success and future strategies	7
Current and preclinical treatment options for Merkel cell carcinoma	6
Extracellular RNAs in pancreatic cancer: from pathogenesis to precision medicine	6
Exploring the inherent susceptibility of cancer-associated fibroblasts to oncolytic virus infection	6
The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?	6
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence	6
Gene therapy for choroideremia: progress, potential and pitfalls	6

Applications of mesenchymal stem cells in ocular surface diseases: sources and routes of delivery	6
Correction	6
Improving care for children with juvenile idiopathic arthritis: the role of IL-6 inhibitors in a patient-centered approach	6
Targeting two pathways at once: the emerging role of bispecific antibodies in NSCLC and SCLC	6
An evaluation of ravulizumab for the treatment of neuromyelitis optica spectrum disorder	6
Advanced therapies targeting IL-23: clinical outcomes in ulcerative colitis	6
Progress in second-line antibody therapies for advanced esophageal squamous cell carcinoma	6
Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?	6
Biological therapies for hemophagocytic lymphohistiocytosis: current knowledge and future perspectives	6
Could siRNA therapeutics change the way we treat dyslipidemia?	6
Comparison of the outcomes between early and late anti-tumor necrosis factor therapy in patients with enthesitis-related subcategory of juvenile idiopathic arthritis: a multi-center study in Southeast	6
Real-world effectiveness and predictors of complete skin clearance (PASI 100) with anti-IL-23 monoclonal antibodies in moderate-to-severe psoriasis: a retrospective cohort study	6
The future of cancer vaccines against colorectal cancer	6
Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting	6
The ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis?	6
Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)?	5
Long-term outcomes and late toxicities of CAR T-cell therapy in large B-cell lymphoma	5
Bintrafusp alfa and its unsuccessful development journey towards cervical cancer treatment	5
Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial	5
Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey	5
The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma	5
Hypoxic storage of red blood cells to improve transfusion outcomes in hematological malignancies	5
A situational analysis of the adoption of oncology, inflammation, and supportive care biosimilars in the United States	5
Oncolytic virus therapy for malignant gliomas: entering the new era	5
Tildrakizumab in the treatment of moderate-to-severe plaque psoriasis: expert insights from Italian real-world experience	5
Infliximab biosimilar GP1111: a review of 5 years’ post-approval experience	5
Does pharmacological intervention prevent or delay the onset of psoriatic arthritis among psoriasis patients?	5
Therapeutic monoclonal antibodies for COVID-19 management: an update	5
Perceptions of airway gene therapy for cystic fibrosis	5
Elotuzumab in multiple myeloma	5
Nivolumab + relatlimab for the treatment of unresectable or metastatic melanoma	5
An evaluation of datopotamab deruxtecan for the treatment of non-small cell lung cancer	5
Recent developments in CD19-targeted therapies for follicular lymphoma	5
Checkpoint inhibition for early-stage hormone receptor-positive breast cancer	5
What does the future hold for antibody-drug conjugate therapies in ovarian cancer?	5
The history of Crohn’s perianal fistula treatment with mesenchymal stem cells: the story of darvadstrocel	5
Navigating the landscape of immune checkpoint inhibitors and novel immunotherapies in melanoma: long-term outcomes, progress, and challenges	5
Literature review and expert opinion on diagnosis and current management of generalized pustular psoriasis	5
An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas	5
Pathogenesis-oriented therapy of psoriasis using biologics	5
Meta-analysis of response rates to first-line salvage treatment after CAR-T therapy failure in large B-cell lymphoma patients	5
Real-life data of etanercept efficacy and safety in juvenile idiopathic arthritis: a 24-month retrospective study at a single center	5
The cell replacement therapeutic potential of human pluripotent stem cells	4
Emerging anti-spike monoclonal antibodies against SARS-CoV-2	4
T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement	4
Clinical advances in biological therapy for generalized pustular psoriasis: a review	4
Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects	4
Chasing optimal first-in-human (FIH) starting dose for biotherapeutics in oncology	4
Taming the beast: engineering strategies and biomedical potential of antibody-based cytokine mimetics	4
Emerging role of monoclonal antibodies in the treatment of IgA nephropathy	4
The evolving therapeutic landscape of diabetic retinopathy	4
Preventing organ damage in systemic lupus erythematosus: the impact of early biological treatment	4
Optimizing the use of vilobelimab for the treatment of COVID-19	4
Efficacy of intravenous infliximab in axial spondyloarthritis: impact on disease activity, quality of life, and productivity in subgroups with psoriasis and inflammatory bowel disease	4
Efficacy and safety of biosimilars in gastroenterology: a focus on inflammatory bowel disease management	4
A randomized, double-masked parallel-group, multicenter clinical study evaluating the efficacy and safety of the biosimilar candidate AVT06 compared to the reference product aflibercept in participant	4
Challenges and opportunities when transitioning from in vivo gene replacement to in vivo CRISPR/Cas9 therapies – a spotlight on hemophilia	4
Short and long-term economic implications of biosimilars	4
Effect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis	4
Targeting IL-17A for the treatment of pustular psoriasis: a comprehensive review	4
Sarilumab in the treatment of rheumatoid arthritis: future perspectives	4
An evaluation of elranatamab for the treatment of myeloma: current evidence for treating relapsed/refractory disease and future directions	4
Perispinal etanercept stroke trial design: PESTO and beyond	4
Biologics for dengue prevention: up-to-date	4
Immunobiology of biliary tract cancer and recent clinical findings in approved and upcoming immune checkpoint inhibitors	4
How treatment choices influence the onset and outcomes of uveitis in juvenile idiopathic arthritis: a retrospective cohort study	4
Monoclonal antibodies as adjuvant therapies for resected melanoma	4
Targeting claudin 18.2 in gastric cancer: a review of emerging biologic agents	4
Ten-year trend of rituximab use for hematological malignancies: a multiregional real-world study using the Italian VALORE distributed database network	4
Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States	4
Transitioning immunotherapy in neuromyelitis optica spectrum disorder – when and how to switch	4
Targeting cervical cancer with anti-PD-1 antibodies: what is new?	4
Safety and effectiveness of efgartigimod for intravenous infusion in patients with generalized myasthenia gravis: an interim analysis of Japanese post-marketing surveillance	4
An evaluation of nipocalimab for the treatment of generalized myasthenia gravis	4
Biosimilar stewardship at the interface of disproportionality methods and AI integration: current evidence and potential strategies	4
Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chron	4
Addressing practical challenges with bispecific antibody therapy in multiple myeloma	4
Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome	4
Should CAR-T cell therapy be considered a standard of care for patients with refractory diffuse large B-cell lymphoma in second line treatment?	4
Conditionally active T cell engagers for the treatment of solid tumors: rationale and clinical development	4
Regulatory and clinical development to support the approval of advanced therapies medicinal products in Japan	4
Correction	4
Efficacy and safety of rituximab in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis	4
The future of CAR T-cell therapy for B-cell acute lymphoblastic leukemia in pediatrics and adolescents	3
Biological therapy in elderly patients with acute myeloid leukemia	3
Switching CGRP(r) MoAbs in migraine: what evidence?	3
Current status of mucosal vaccines against SARS-CoV2: a hope for protective immunity	3
What is ‘ chronic ’ pustular psoriasis? Identifying candidates for long-term subcutaneous spesolimab treatment	3
Successes and failures: the latest advances in the clinical development of amyloid–β–targeting monoclonal antibodies for treating Alzheimer's disease	3
Management of metastatic melanoma with combinations including PD-1 inhibitors	3
Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer	3
IgG-VHH bispecific fusion antibodies: challenges and opportunities as therapeutic agents	3
Recent developments and industry interest in gene therapy for Duchenne muscular dystrophy	3
Clinical use of intravenous immunoglobulin in juvenile dermatomyositis: indications, treatment course, and clinical outcomes	3
Antibody-based therapeutics for chronic rhinosinusitis with nasal polyps	3